Abstract
Objective
To assess the metabolic drug toxicities of first-line, World Health Organization (WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens, to estimate the prevalence of body fat redistribution and to identify associated risk factors.
Methods
Cross-sectional observational study. During 3 month period, 52 HIV infected children (25 on HAART; 27 not on HAART) were assessed. Their sociodemographic, clinical, and immunological data was recorded. Children were examined or the signs of fat redistribution (peripheral lipoatrophy and central lipohypertrophy). Liver function tests, fasting blood sugar, lipid profile, serum amylase, serum lactate, blood pH and bicarbonate levels were done in all patients.
Results
Twenty-two patients were on stavudine and three on zidovudine based HAART. None of the patients ever received any protease inhibitor. There were no cases of clinical or immunological failure. Children on HAART had significantly lower weight for age and body mass index but the mean height for age was similar between study groups. Only two cases of peripheral lipoatrophy were observed. Hypercholesterolemia was observed in four children on HAART but none without therapy. Hypertriglyceridemia was observed in three children on HAART and seven without therapy. Four cases of asymptomatic mild hyperlactatemia were observed. No case of any hyperglycemia or liver impairment was observed.
Conclusion
Metabolic abnormalities and lipodystrophy are emerging complications of HAART in Indian children and needs very close follow up. Future studies with larger sample size and longitudinal model are recommended.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Carr A, Samaras K, Thorsidottir A, Kaufman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.
Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabet Metab 1999, 25:383–392.
Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493–2505.
John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9–20.
Chen DS, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845–4856.
Leow MK, Addy CL, Mantzoros CS. Clinical review 159. Human immunodeficiency virus/highly active antiretroviral therapy associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961–1976.
Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organizationrecommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39: 199–202.
Saghayam S, Chaguturu SK, Kumarasamy N, Solomon S, Mayer KH, Wanke C. Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis 2004; 38: 1646–1647.
Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405–410.
Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, Allen HF. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003; 22: 463–465.
European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIVinfected children in Europe. AIDS 2004; 18: 1443–1451.
Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164: 271–276.
Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitorcontaining, highly active antiretroviral therapy regimens. Pediatrics 2004; 114: e235–e242.
Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166: 13–21.
Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 427–431.
Ergun-Longmire B, Lin-Su K, Dunn AM, Chan L, Ham K, Sison C et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 2006; 12: 514–521.
Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P et al. Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41: 453–460.
Solórzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G, Vázquez Rosales G, Miranda Novales MG. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 2006; 37: 129–132.
Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005; 88: 956–966.
Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIVinfected children. J Acquir Immune Defic Syndr 2005; 40: 161–168.
World Health Organization. Scaling up Antiretroviral Therapy in Resourcelimited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2003.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13–23.
Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIVinfected adults: a case-control study. Lancet 2003; 361:726–735.
Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33:571–576.
Lauer R, Barness LA, Clark R. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992; 89: 525–584.
Divisions of AIDS, National Institute of Allergy and Infectious Diseases. Toxicity table for grading severity of pediatric adverse experiences. April 1994. Available at: http://www.hptn.org/Web%20Documents/Regulatory_Resources.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Parakh, A., Dubey, A.P., Kumar, A. et al. Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr 76, 1017–1021 (2009). https://doi.org/10.1007/s12098-009-0216-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-009-0216-9